Drug class
Primary bile acid; farnesoid X receptor (FXR) ligand and bile-acid metabolic substrate
Mechanism of action
Acts as an endogenous bile acid that facilitates intestinal absorption of dietary fats and fat-soluble vitamins. It also activates FXR and regulates bile-acid synthesis and transport. Therapeutic effects in cerebrotendinous xanthomatosis (CTX) involve replacement of deficient bile-acid feedback and suppression of abnormal bile-acid precursor synthesis.
General use cases
- Treatment of cerebrotendinous xanthomatosis (CTX) in adults and eligible paediatric patients using authorised chenodeoxycholic acid products; other gallstone-dissolution uses are historical or product-specific and should not be assumed
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
